• Citer

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

par Shi, W;Jiang, T;Nuciforo, Paolo;Hatzis, Christos;Holmes, E;Harbeck, Nadia;Sotiriou, Christos ;Peña, L;Loi, Sherene ;Rosa, D D;Chia, S;Wardley, Andrew;Ueno, T;Rossari, José ;Eidtmann, H;Armour, A;Piccart-Gebhart, Martine ;Rimm, David D.L.;Baselga, José;Pusztai, Lajos
Référence Annals of oncology, 28(1), page (128-135)
Publication Publié, 2017-01-01

Article révisé par les pairs

• Détails
• Contenu

Titre:	Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Auteur:	Shi, W; Jiang, T; Nuciforo, Paolo; Hatzis, Christos; Holmes, E; Harbeck, Nadia; Sotiriou, Christos; Peña, L; Loi, Sherene; Rosa, D D; Chia, S; Wardley, Andrew; Ueno, T; Rossari, José; Eidtmann, H; Armour, A; Piccart-Gebhart, Martine; Rimm, David D.L.; Baselga, José; Pusztai, Lajos
Informations sur la publication:	Annals of oncology, 28(1), page (128-135)
Statut de publication:	Publié, 2017-01-01
Sujet CREF:	Cancérologie
	Médecine pathologie humaine
	Sciences bio-médicales et agricoles
Mots-clés:	PIK3CA-related network
	breast cancer NeoALTTO trial
	regulation of RhoA activity
	whole-exome sequencing
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0923-7534
	info:doi/10.1093/annonc/mdw434
	info:pii/mdw434
	info:scp/85015720647
	info:pmid/27687302